PubMed Health⌕ Search

PubMed · 7694349

Multiple imputation for threshold-crossing data with interval censoring.

Abstract

Medical statistics often involve measurements of the time when a variable crosses a threshold value. The time to threshold crossing may be the outcome variable in a survival analysis, or a time-dependent covariate in the analysis of a subsequent event. This paper presents new methods for analysing threshold-crossing data that are interval censored in that the time of threshold crossing is known only within a specified interval. Such data typically arise in event-history studies when the threshold is crossed at some time between data-collection points, such as visits to a clinic. We propose methods based on multiple imputation of the threshold-crossing time with use of models that take into account values recorded at the times of visits. We apply the methods to two real data sets, one involving hip replacements and the other on the prostate specific antigen (PSA) assay for prostate cancer. In addition, we compare our methods with the common practice of imputing the threshold-crossing time as the right endpoint of the interval. The two examples require different imputation models, but both lead to simple analyses of the multiply imputed data that automatically take into account variability due to imputation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F J Dorey, R J Little, N Schenker. 1993-09-15. Multiple imputation for threshold-crossing data with interval censoring.. https://doi.org/10.1002/sim.4780121706

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Clinical trials in the new millennium.

Since the introduction of the randomized clinical trial (RCT) over 50 years ago, this method has become the corner stone for evaluating new pharmacologic or biologic agents with many disease areas benefiting. There are numerous examples demonstrating beneficial interventions as well as others either not beneficial or harmful. Statistical methodology for clinical trials has grown rapidly. Advances in information technology for data collection have allowed trials to be conducted around the world. Academia, industry and government have worked in partnership to conduct RCTs. Despite these many RCT achievements, the most interesting and challenging era of clinical trials lies ahead of us. With the human genome now sequenced, we face a new set of challenges to transform vast amounts of data into useful information. The post-genomics era will better identify the disease mechanism and thus help design better treatments, and be more selective in screening patients, yielding more efficient clinical trials. For some areas of medicine, such as medical devices, standards of acceptance and regulatory approval are changing. Other areas, such as medical procedures and alternative medicines, are generally not well evaluated and could benefit greatly from a wider use of RCT methodology. As the ICH guidelines facilitate and encourage international clinical trials, the scientific and ethical dimension of conducting trials in Third World countries are raised. For example, Western society's best standard of care may not be available or affordable to these countries as the control Western investigators should not exploit patients in the Third World. Those and many other challenges face us in the decade ahead. It is truly an exciting time with new opportunities for the RCT to contribute to medicine and health care or prevention.

Data Interpretation, Statistical↗